Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17115747 | METHODS OF SUBJECTING BIOMASS SOLIDS TO AT LEAST ONE DISRUPTION PROCESS AFTER THE BIOMASS SOLIDS HAVE BEEN EXPOSED TO AT LEAST FERMENTATION, AND RELATED SYSTEMS | December 2020 | November 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 17111537 | DETERGENT COMPOSITION | December 2020 | January 2024 | Abandon | 38 | 1 | 0 | No | No |
| 16953050 | ENGINEERED MICROORGANISMS & METHODS FOR IMPROVED CROTYL ALCOHOL PRODUCTION | November 2020 | January 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17070726 | KIND OF METHOD FOR PREPARING L-CITRULLINE BY USING AEROMONAS SP. | October 2020 | October 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17063116 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | October 2020 | March 2022 | Abandon | 17 | 0 | 1 | No | No |
| 16963084 | Microorganisms With Improved Nitrogen Utilization For Ethanol Production | July 2020 | June 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16919104 | ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID | July 2020 | January 2022 | Abandon | 18 | 1 | 0 | No | No |
| 16955801 | NEW XYLANASE WITH IMPROVED THERMOSTABILITY AND INCREASED ENZYME ACTIVITY ON ARABINOXYLAN | June 2020 | February 2022 | Abandon | 20 | 0 | 1 | No | No |
| 16759099 | METHODS FOR PRODUCING A MHC MULTIMER | April 2020 | October 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16851970 | Methods and Materials for Producing Polyols and Electron Rich Compounds | April 2020 | March 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16754130 | COMPOSITIONS AND METHODS FOR MAKING SELENOCYSTEINE CONTAINING POLYPEPTIDES | April 2020 | September 2022 | Allow | 29 | 0 | 1 | Yes | No |
| 16836335 | ACTIVATING MITOTIC CHECKPOINT CONTROL MECHANISMS | March 2020 | March 2023 | Abandon | 36 | 2 | 1 | Yes | No |
| 16650325 | PREPARATION OF GLYCOGENIC-LIPOGENIC PRECURSORS IN THE PELLET FORM TO ENHANCE FERTILITY IN COWS DURING EARLY POSTPARTUM PHASE AND SHEEP DURING FLUSHING PHASE | March 2020 | March 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16645219 | IMPROVED WASHING PERFORMANCE USING A NOVEL ALPHA-AMYLASE FROM FOMITOPSIS PINICOLA (FPI) | March 2020 | March 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16794784 | CYTOCHROME P450 AND CYTOCHROME P450 REDUCTASE POLYPEPTIDES, ENCODING NUCLEIC ACID MOLECULES AND USES THEREOF | February 2020 | March 2022 | Abandon | 25 | 2 | 1 | No | No |
| 16694097 | BIOSYNTHESIS OF HUMAN MILK OLIGOSACCHARIDES IN ENGINEERED BACTERIA | November 2019 | January 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16509700 | GLYCEROL AND ACETIC ACID CONVERTING YEAST CELLS WITH IMPROVED ACETIC ACID CONVERSION | July 2019 | May 2023 | Allow | 46 | 4 | 1 | No | Yes |
| 16296705 | COMPOSITION COMPRISING RECOMBINANT CLOSTRIDIUM NEUROTOXIN | March 2019 | September 2022 | Allow | 43 | 4 | 0 | Yes | No |
| 16329176 | ENGINEERED SUBTILIGASE VARIANTS FOR VERSATILE, SITE-SPECIFIC LABELING OF PROTEINS | February 2019 | December 2022 | Abandon | 45 | 3 | 1 | Yes | No |
| 16277335 | Amylases, Nucleic Acids Encoding Them and Methods for Making and Using Them | February 2019 | January 2022 | Abandon | 35 | 2 | 1 | Yes | No |
| 16068410 | LACTIC ACID-UTILIZING BACTERIA GENETICALLY MODIFIED TO SECRETE POLYSACCHARIDE-DEGRADING ENZYMES | July 2018 | January 2022 | Abandon | 42 | 3 | 2 | Yes | No |
| 15779268 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF HYDROCARBONS, HYDROGEN AND CARBON MONOXIDE USING ENGINEERED AZOTOBACTER STRAINS | May 2018 | January 2022 | Abandon | 44 | 3 | 2 | No | No |
| 15819901 | STORAGE-STABLE LIQUID DETERGENT OR CLEANING AGENT CONTAINING PROTEASE AND LIPASE | November 2017 | May 2023 | Abandon | 60 | 7 | 1 | Yes | No |
| 15804507 | STORAGE STABLE LIQUID WASHING OR CLEANING AGENT CONTAINING PROTEASE AND CELLULASE | November 2017 | May 2023 | Abandon | 60 | 7 | 1 | Yes | No |
| 15793576 | WASHING OR CLEANING AGENT COMPRISING A PROTEASE AND AN AMYLASE | October 2017 | April 2023 | Abandon | 60 | 7 | 0 | Yes | No |
| 15520844 | SERINE PROTEASES | April 2017 | March 2020 | Abandon | 35 | 4 | 0 | No | No |
| 15311188 | HIGHER PERFORMANCE PROTEASES FOR SCARLESS PEPTIDE TAG REMOVAL | March 2017 | January 2023 | Abandon | 60 | 3 | 1 | Yes | Yes |
| 15355663 | PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS | November 2016 | January 2022 | Abandon | 60 | 6 | 1 | No | No |
| 14173483 | 2-Deoxy-Scyllo-Inosose Synthase | February 2014 | April 2015 | Abandon | 14 | 1 | 0 | No | No |
| 14082000 | ADIPATE (ESTER OR THIOESTER) SYNTHESIS | November 2013 | August 2016 | Abandon | 33 | 0 | 0 | No | No |
| 13862626 | METHOD FOR THE PRODUCTION OF 1-BUTANOL | April 2013 | December 2014 | Abandon | 20 | 2 | 0 | Yes | No |
| 13799972 | MUTANT PROTEASES AND METHODS OF USE THEREOF | March 2013 | March 2015 | Abandon | 24 | 1 | 1 | No | No |
| 13636960 | Bacillus Pumilus Bilirubin Oxidase and Applications Thereof | December 2012 | January 2015 | Abandon | 28 | 2 | 1 | No | No |
| 13656086 | ENGINEERED MICROBES AND METHODS FOR MICROBIAL OIL PRODUCTION | October 2012 | August 2014 | Allow | 22 | 1 | 1 | Yes | No |
| 13139824 | PRODUCTION OF ETHANOL FROM LIGNOCELLULOSIC BIOMASS | January 2012 | January 2015 | Abandon | 44 | 3 | 0 | Yes | No |
| 13034198 | NOVEL SELF-DYING RECOMBINANT MICROORGANISM FOR MEASURING SOIL AND WATER CONTAMINATION | February 2011 | June 2013 | Allow | 28 | 1 | 0 | No | No |
| 11703398 | Claudin polypeptides, polynucleotides, and methods of making and use thereof | February 2007 | June 2008 | Abandon | 17 | 0 | 1 | No | No |
| 11650813 | NOVEL RAT CALCIUM CHANNEL SUBUNITS AND RELATED PROBES, CELL LINES AND METHODS | January 2007 | July 2007 | Allow | 6 | 0 | 1 | No | No |
| 11637012 | METHOD FOR ATTACHING TWO SURFACES TO EACH OTHER USING A BIOADHESIVE POLYPHENOLIC PROTEIN AND PERIODATE IONS | December 2006 | February 2008 | Allow | 14 | 1 | 0 | No | No |
| 11637011 | METHOD FOR ATTACHING TWO SURFACES TO EACH OTHER USING A BIOADHESIVE POLYPHENOLIC PROTEIN AND PERIODATE IONS | December 2006 | February 2008 | Allow | 14 | 1 | 0 | No | No |
| 11542050 | THERAPEUTIC FIBRIN-DERIVED PEPTIDES AND USES THEREOF | October 2006 | July 2008 | Allow | 21 | 1 | 1 | No | No |
| 11466274 | METHODS AND KITS FOR PURIFYING HIS-TAGGED PROTEINS | August 2006 | October 2007 | Allow | 14 | 1 | 1 | No | No |
| 11489644 | NOVEL BT TOXIN RECEPTORS AND METHODS OF USE | July 2006 | February 2007 | Allow | 6 | 0 | 1 | No | No |
| 11480822 | STARS-A MUSCLE-SPECIFIC ACTIN-BINDING PROTEIN | July 2006 | March 2008 | Allow | 20 | 1 | 0 | No | No |
| 11478461 | Phosphokinase and the usage thereof | June 2006 | November 2007 | Abandon | 17 | 1 | 1 | No | No |
| 11437418 | CELL CULTURE PERFORMANCE WITH BETAINE | May 2006 | January 2008 | Allow | 20 | 2 | 1 | No | Yes |
| 11397310 | USE OF THROMBIN-DERIVED PEPTIDES FOR THE THERAPY OF CHRONIC DERMAL ULCERS | April 2006 | January 2008 | Allow | 22 | 1 | 1 | No | No |
| 11389947 | COMPOSITIONS AND METHODS FOR REGULATING RNA STABILITY USING POLYPYRIMIDINE TRACT PROTEINS | March 2006 | December 2006 | Allow | 9 | 0 | 0 | No | No |
| 11374724 | Neuroprotective complex for treatment of cerebral ischemia and injury | March 2006 | January 2008 | Abandon | 22 | 1 | 1 | No | No |
| 10544809 | APOPTOSIS-INDUCING GENE AND UTILIZATION OF THE SAME | February 2006 | April 2008 | Allow | 33 | 1 | 1 | No | No |
| 10538410 | Protein forming complex with c-fos protein, nucleic acid encoding the same and method of using the same | February 2006 | April 2008 | Abandon | 34 | 2 | 1 | No | No |
| 11351523 | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | February 2006 | July 2007 | Abandon | 17 | 0 | 1 | No | No |
| 11342867 | Charged phospholipid compositions and methods for their use | January 2006 | July 2008 | Abandon | 30 | 2 | 1 | No | No |
| 10520023 | Use of an acidic aqueous solution of a bioadhesive polyphenolic protein as an adhesive or coating | December 2004 | October 2007 | Abandon | 33 | 2 | 1 | No | No |
| 11024424 | SMART BIO-NANOPARTICLE ELEMENTS | December 2004 | May 2008 | Allow | 40 | 2 | 1 | No | No |
| 10505546 | Cat immunisation vectors | December 2004 | November 2006 | Abandon | 27 | 0 | 1 | No | No |
| 11004455 | Labeling of proteomic samples during proteolysis for quantitation and sample multiplexing | December 2004 | May 2007 | Abandon | 30 | 0 | 1 | No | No |
| 10500913 | USE OF ERYTHROPOIETIN FOR THE PREVENTIVE OR CURATIVE TREATMENT OF CARDIAC FAILURE | November 2004 | July 2007 | Allow | 36 | 2 | 1 | No | No |
| 10996570 | METHODS AND APPARATUS FOR CREATING PARTICLE DERIVATIVES OF HDL WITH REDUCED LIPID CONTENT | November 2004 | January 2008 | Allow | 38 | 4 | 0 | Yes | No |
| 10509307 | C-jun phosphorylation inhibitors | November 2004 | March 2008 | Abandon | 42 | 1 | 1 | No | No |
| 10984821 | Mutant phosphoribosylpyrophosphate synthetase and method for producing L-histidine | November 2004 | August 2008 | Abandon | 45 | 2 | 1 | Yes | No |
| 10971748 | Apparatuses and processes for increasing protein PEGylation reaction yields | October 2004 | January 2007 | Abandon | 27 | 1 | 1 | No | No |
| 10973045 | ALSTROEM SYNDROME GENE, GENE VARIANTS, EXPRESSED PROTEIN AND METHODS OF DIAGNOSIS FOR ALSTROEM SYNDROME | October 2004 | November 2006 | Allow | 25 | 1 | 1 | No | No |
| 10965972 | CLAUDIN POLYPEPTIDES, POLYNUCLEOTIDES, AND METHODS OF MAKING AND USE THEREOF | October 2004 | November 2006 | Allow | 25 | 1 | 1 | No | No |
| 10967061 | PHARMACEUTICAL FORMULATIONS, METHODS, AND DOSING REGIMENS FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | October 2004 | July 2008 | Allow | 45 | 3 | 1 | No | No |
| 10964950 | Method and apparatus for preparing bone | October 2004 | June 2007 | Abandon | 32 | 0 | 1 | No | No |
| 10958298 | METHOD FOR MODIFYING PROTEIN OR PEPTIDE C-TERMINAL | October 2004 | July 2007 | Allow | 33 | 2 | 1 | No | No |
| 10960409 | Alternatively spliced isoforms of nuclear factor kappa-B, subunit 1 (NFKB1) | October 2004 | November 2006 | Abandon | 25 | 0 | 1 | No | No |
| 10958858 | Novel human collagen proteins and polynucleotides encoding the same | October 2004 | December 2006 | Abandon | 26 | 1 | 1 | No | No |
| 10956065 | CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE | October 2004 | December 2007 | Allow | 38 | 2 | 1 | No | No |
| 10509401 | METHOD FOR ATTACHING TWO SURFACES TO EACH OTHER USING A BIOADHESIVE POLYPHENOLIC PROTEIN AND PERIODATE IONS | September 2004 | October 2006 | Allow | 25 | 1 | 1 | No | No |
| 10942300 | Compositions capable of facilitating penetration across a biological barrier | September 2004 | March 2008 | Abandon | 42 | 2 | 1 | No | No |
| 10927675 | ARTIFICIAL OXYGEN CARRIER AND PRODUCTION METHOD THEREOF | August 2004 | May 2007 | Allow | 33 | 2 | 1 | No | No |
| 10490795 | Ferroportin-1 mutant | August 2004 | September 2007 | Abandon | 42 | 2 | 1 | No | No |
| 10924081 | NOVEL RAT CALCIUM CHANNEL SUBUNITS AND RELATED PROBES, CELL LINES AND METHODS | August 2004 | October 2006 | Allow | 26 | 1 | 1 | No | No |
| 10484373 | Mannose binding lectin and uses thereof | August 2004 | July 2008 | Abandon | 54 | 2 | 1 | No | Yes |
| 10913697 | METHODS FOR MODULATING A DRUG-RELATED EFFECT OR BEHAVIOR | August 2004 | July 2007 | Allow | 36 | 2 | 1 | No | No |
| 10485233 | XOBESIN AGONISTS AND ANTAGONISTS FOR THE TREATMENT OF METABOLIC DISORDERS | August 2004 | May 2007 | Allow | 39 | 2 | 1 | No | No |
| 10909204 | Avian sternal cartilage composition and method of administering | July 2004 | March 2008 | Abandon | 43 | 3 | 1 | No | No |
| 10902489 | Use of soluble P-selectin and anthrax lethal toxin | July 2004 | February 2007 | Abandon | 31 | 1 | 1 | No | No |
| 10901243 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | July 2004 | January 2007 | Abandon | 29 | 0 | 1 | No | No |
| 10896555 | FAMILY 44 XYLOGLUCANASES | July 2004 | November 2007 | Allow | 39 | 1 | 1 | No | No |
| 10896455 | HEMOSTATIC DEVICE CONTAINING A PROTEIN PRECIPITATE | July 2004 | October 2006 | Allow | 27 | 1 | 1 | No | No |
| 10887540 | ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis | July 2004 | March 2007 | Abandon | 32 | 1 | 1 | No | No |
| 10483150 | EXPRESSION SYSTEM | June 2004 | July 2006 | Abandon | 30 | 3 | 0 | No | Yes |
| 10499184 | C-TYPE LECTIN POLYPEPTIDES | June 2004 | December 2007 | Allow | 42 | 2 | 1 | No | No |
| 10498793 | METHOD AND KIT PROVIDING BIOADHESIVE BINDING OR COATING WITH POLYPHENOLIC MUSSEL PROTEINS | June 2004 | July 2007 | Allow | 37 | 3 | 1 | No | No |
| 10866330 | COMPOSITIONS AND METHODS FOR TREATING ATHEROSCLEROSIS | June 2004 | May 2007 | Allow | 36 | 3 | 1 | Yes | No |
| 10849540 | METHODS OF REDUCING VASCULAR PERMEABILITY IN TISSUE BY INHIBITION OF TISSUE PLASMINOGEN ACTIVATOR (TPA) AND TPA INHIBITORS USEFUL THEREIN | May 2004 | January 2008 | Allow | 44 | 2 | 1 | No | No |
| 10819352 | PHARMACEUTICAL COMPOSITION CONTAINING ARTIFICIAL OXYGEN CARRIER | April 2004 | April 2008 | Allow | 48 | 5 | 1 | No | No |
| 10806930 | NUCLEIC ACIDS ENCODING LINKED CHROMO/FLUORESCENT DOMAINS AND METHODS FOR USING THE SAME | March 2004 | October 2006 | Allow | 31 | 5 | 0 | No | No |
| 10798058 | NOVEL BT TOXIN RECEPTORS AND METHODS OF USE | March 2004 | December 2006 | Allow | 33 | 1 | 1 | No | No |
| 10796691 | METHODS AND APPARATUS FOR CREATING PARTICLE DERIVATIVES OF HDL WITH REDUCED LIPID CONTENT | March 2004 | March 2008 | Allow | 48 | 5 | 1 | No | No |
| 10789956 | POLYMER-FACTOR VIII MOIETY CONJUGATES | February 2004 | October 2006 | Allow | 32 | 3 | 1 | No | No |
| 10477712 | Process for producing peptide | February 2004 | May 2007 | Abandon | 42 | 1 | 1 | No | No |
| 10771004 | Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction | February 2004 | October 2007 | Abandon | 44 | 2 | 2 | No | No |
| 10474647 | ANTIMICROBIAL POLYPEPTIDE FROM ASPERGILLUS NIGER | October 2003 | September 2007 | Allow | 47 | 1 | 1 | No | No |
| 10473364 | METHOD FOR INCREASING PRODUCTIVITY OF SECONDARY METABOLITE BY CONFERRING DRUG-RESISTANT MUTATIONS | September 2003 | July 2007 | Allow | 46 | 3 | 1 | Yes | No |
| 10666223 | PROCESS FOR EXTRACTING THE COMPONENTS OF PEA FLOUR | September 2003 | October 2006 | Allow | 37 | 3 | 1 | No | No |
| 10659004 | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | September 2003 | November 2006 | Abandon | 38 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONDESI, ROBERT B.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MONDESI, ROBERT B works in Art Unit 1652 and has examined 117 patent applications in our dataset. With an allowance rate of 49.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner MONDESI, ROBERT B's allowance rate of 49.6% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MONDESI, ROBERT B receive 2.05 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MONDESI, ROBERT B is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -8.9% benefit to allowance rate for applications examined by MONDESI, ROBERT B. This interview benefit is in the 4% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 18.6% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.4% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 84.6% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 91.3% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 31.6% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.